Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 01:30:02 01/07/2026 am IST			5-day change	1st Jan Change
32.73 ^USD	-4.88%		+0.58%	-19.38%

29/06	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
29/06	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

ce375bc66103e5f.7jkJ6pNnoGc-tTQinI_5dDxM0fjbDvm2Ixie8JzKcMk.iQ87sssi1BdL3mVA2-LKRQUFg7fvQb7ZW3bfo9mFMf-eAVi__zbPVVLXRw~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

29/06	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
29/06	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
18/05	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
17/03	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
12/25/12	Conmed Shares Fall After Needham Downgrade	MT
12/25/12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/25/28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
06/25/06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/24/01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/24/25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
25/24/25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/24/25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
01/24/01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
01/24/01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/23/27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
26/23/26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/23/05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/23/22	CL King Starts CONMED at Buy With $140 Price Target	MT
27/23/27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
27/23/27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT
27/23/27	CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	+15.08%
ABBOTT LABORATORIES		+25.71%
MEDTRONIC PLC		+20.81%
CENCORA, INC.		+24.62%
HOYA CORPORATION		+17.73%
BECTON, DICKINSON AND COMPANY		+14.54%
MEDLINE INC.		+29.13%
DEXCOM, INC.		+21.81%
WEST PHARMACEUTICAL SERVICES, INC.		+1.16%
STERIS PLC		+20.45%
Average		+19.10%
Weighted average by Cap.		+21.51%